Mark Carlson, MD
Internal Medicine · Cedar Park, TXNPI 1023008398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Eisai Inc. at 27.2% of the total. That places this record below the midpoint for internal medicine clinicians in TX, where the typical reported total is $270.
Across 18 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$97
- E.r. Squibb & Sons, L.L.C.$84
- Johnson & Johnson$40
- Amgen$21
- Merck$17
- Clovis Oncology, Inc.$16
- plus $81 from 6 others
Across 1,367 payments — averaging $4832.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$2M
- Vertex$1.7M
- Janssen Research & Development, LLC$966K
- Pfizer$472K
- Bavarian Nordic A/s$429K
- Sanofi Pasteur Inc.$351K
- plus $742K from 10 others
What the payments were for
- Food & beverage$357100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 2 | $97 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84 |
| Johnson & Johnson | 2 | $40 |
| Amgen | 1 | $21 |
| Merck | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Seagen Inc. | 1 | $11 |
How this compares
$357 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $11,218 |
| EliquisApixaban | 13 | $7,462 |
| Propranolol Hcl ErPropranolol Hcl | 28 | $1,535 |
| Donepezil Hcl | 53 | $1,006 |
| Potassium Chloride | 46 | $910 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $871 |
| Duloxetine Hcl | 14 | $820 |
| Levothyroxine Sodium | 71 | $739 |
| Divalproex Sodium | 21 | $724 |
| Atorvastatin Calcium | 49 | $722 |
| Gabapentin | 45 | $702 |
| Memantine Hcl | 13 | $525 |
| Furosemide | 77 | $507 |
| Amlodipine Besylate | 47 | $501 |
| Diltiazem Hcl | 13 | $471 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Cedar Park
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.